These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25413708)

  • 1. Label-free MS imaging from drug discovery to preclinical development.
    Hochart G; Hamm G; Stauber J
    Bioanalysis; 2014 Oct; 6(20):2775-88. PubMed ID: 25413708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated quantitative and qualitative workflow for in vivo bioanalytical support in drug discovery using hybrid Q-TOF-MS.
    Ranasinghe A; Ramanathan R; Jemal M; D'Arienzo CJ; Humphreys WG; Olah TV
    Bioanalysis; 2012 Mar; 4(5):511-28. PubMed ID: 22409550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Current Use of Mass Spectrometry in Combination with Oth er Separation Techniques in Drug Discovery Arena.
    Kawczak P; Baczek T
    Med Chem; 2016; 12(5):404-11. PubMed ID: 26732114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Troubleshooting and deconvoluting label-free cell phenotypic assays in drug discovery.
    Fang Y
    J Pharmacol Toxicol Methods; 2013; 67(2):69-81. PubMed ID: 23340025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inductively coupled plasma-MS in drug development: bioanalytical aspects and applications.
    van Heuveln F; Meijering H; Wieling J
    Bioanalysis; 2012 Aug; 4(15):1933-65. PubMed ID: 22943623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
    Gabrielsson J; Green AR
    J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mass spectrometry-based biomarkers in drug development.
    Miller RA; Spellman DS
    Adv Exp Med Biol; 2014; 806():341-59. PubMed ID: 24952191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development.
    Agoram BM; Demin O
    Drug Discov Today; 2011 Dec; 16(23-24):1031-6. PubMed ID: 22020181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Label-free in situ monitoring of histone deacetylase drug target engagement by matrix-assisted laser desorption ionization-mass spectrometry biotyping and imaging.
    Munteanu B; Meyer B; von Reitzenstein C; Burgermeister E; Bog S; Pahl A; Ebert MP; Hopf C
    Anal Chem; 2014 May; 86(10):4642-7. PubMed ID: 24559101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application and challenges in using LC-MS assays for absolute quantitative analysis of therapeutic proteins in drug discovery.
    Zheng J; Mehl J; Zhu Y; Xin B; Olah T
    Bioanalysis; 2014 Mar; 6(6):859-79. PubMed ID: 24702115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MALDI imaging mass spectrometry: bridging biology and chemistry in drug development.
    Castellino S; Groseclose MR; Wagner D
    Bioanalysis; 2011 Nov; 3(21):2427-41. PubMed ID: 22074284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mining the potential of label-free biosensors for seven-transmembrane receptor drug discovery.
    Rocheville M; Martin J; Jerman J; Kostenis E
    Prog Mol Biol Transl Sci; 2013; 115():123-42. PubMed ID: 23415093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoproteomics and Chemical Probes for Target Discovery.
    Drewes G; Knapp S
    Trends Biotechnol; 2018 Dec; 36(12):1275-1286. PubMed ID: 30017093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acoustic mist ionization mass spectrometry (AMI-MS) as a drug discovery platform.
    Sinclair I; Davies G; Semple H
    Expert Opin Drug Discov; 2019 Jul; 14(7):609-617. PubMed ID: 31081699
    [No Abstract]   [Full Text] [Related]  

  • 15. Metabolomics in drug discovery and development.
    Robertson DG; Frevert U
    Clin Pharmacol Ther; 2013 Nov; 94(5):559-61. PubMed ID: 24145714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Label-free screening assays: a strategy for finding better drug candidates.
    Lunn CA
    Future Med Chem; 2010 Nov; 2(11):1703-16. PubMed ID: 21428840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of pharmacokinetic and pharmacokinetic/pharmacodynamic modeling in drug discovery and development.
    Yu XQ; Wilson AG
    Future Med Chem; 2010 Jun; 2(6):923-8. PubMed ID: 21426110
    [No Abstract]   [Full Text] [Related]  

  • 18. Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?
    Deng R; Jin F; Prabhu S; Iyer S
    Expert Opin Drug Metab Toxicol; 2012 Feb; 8(2):141-60. PubMed ID: 22248267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Native MS: an 'ESI' way to support structure- and fragment-based drug discovery.
    Vivat Hannah V; Atmanene C; Zeyer D; Van Dorsselaer A; Sanglier-Cianférani S
    Future Med Chem; 2010 Jan; 2(1):35-50. PubMed ID: 21426045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applications of HILIC for targeted and non-targeted LC/MS analyses in drug discovery.
    Onorato JM; Langish R; Bellamine A; Shipkova P
    J Sep Sci; 2010 Mar; 33(6-7):923-9. PubMed ID: 20127913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.